Oligodendroglioma Clinical Trials

Find Oligodendroglioma Clinical Trials Near You

A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

Status: Recruiting
Location: See all (12) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review \[BICR\] per modified Response Assessment in Neuro-Oncology \[RANO\] 2.0), and are not in need of immediate chemotherapy or radiotherapy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Histologically confirmed Grade 2 or 3 IDH-mutant astrocytoma or IDH-mutant and 1p19q co-deleted oligodendroglioma, according to WHO CNS 2021 criteria

• IDH1 mutation (e.g., R132H/C/G/S/L) based on immunohistochemistry (IHC) (R132H only), PCR, or next generation sequencing (NGS).

• Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, or gross total resection).

• Measurable disease per modified RANO 2.0 confirmed by BICR during Screening.

• Previously treated with vorasidenib and experienced radiographic disease progression during treatment and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator. Disease progression must be confirmed by BICR using modified RANO 2.0.

• Adequate hematologic and organ function

• Expected survival of ≥12 months

Locations
United States
California
University of California, Los Angeles
NOT_YET_RECRUITING
Los Angeles
University of California, San Francisco
NOT_YET_RECRUITING
San Francisco
Connecticut
Yale University
NOT_YET_RECRUITING
New Haven
Florida
University of Miami Health
NOT_YET_RECRUITING
Miami
Indiana
Indiana University
NOT_YET_RECRUITING
Indianapolis
Louisiana
LSU LCMC Health Cancer Center
NOT_YET_RECRUITING
New Orleans
Massachusetts
Massachusetts General Hospital
NOT_YET_RECRUITING
Boston
New Jersey
Rutgers Cancer Institute
NOT_YET_RECRUITING
New Brunswick
New York
Columbia University Medical Center
NOT_YET_RECRUITING
New York
NYU Langone Health
RECRUITING
New York
Ohio
Cleveland Clinic
NOT_YET_RECRUITING
Cleveland
The Ohio State University Comprehensive Cancer Center
NOT_YET_RECRUITING
Columbus
Contact Information
Primary
Clinical Trials at Nuvation Bio
ClinicalTrials@nuvationbio.com
332-208-6102
Time Frame
Start Date: 2027-03
Estimated Completion Date: 2032-03
Participants
Target number of participants: 40
Treatments
Experimental: Safusidenib
Safusidenib 250 mg BID
Sponsors
Leads: Nuvation Bio Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials